Retinal Capillary Haemangioblastoma: Clinical Spectrum, Imaging Insights, and Treatment Strategies

视网膜毛细血管母细胞瘤:临床表现、影像学特征和治疗策略

阅读:1

Abstract

BACKGROUND: Retinal capillary haemangioblastoma (RCH) is a benign but potentially vision-threatening vascular tumour of the retina. It may occur sporadically or as multifocal, bilateral lesions in association with von Hippel-Lindau (VHL) disease, often serving as the first manifestation of this multisystem disorder. The pathogenesis involves dysregulated angiogenesis through hypoxia-inducible factor (HIF) pathways, resulting in capillary proliferation and stromal recruitment. SUMMARY: RCHs may present as asymptomatic peripheral lesions or as juxtapapillary tumours, leading to exudation, retinal detachment, and vision loss. Classification based on anatomical location and growth pattern (endophytic, exophytic, sessile) aids prognostication and treatment planning. Diagnosis relies on multimodal imaging, including fluorescein angiography, optical coherence tomography (OCT), OCT angiography, and occasionally indocyanine green angiography. Treatment is individualized according to tumour size, location, and complications, ranging from laser photocoagulation, cryotherapy, photodynamic therapy, and intravitreal anti-vascular endothelial growth factor (VEGF) injections to vitrectomy for tractional complications. Recently, systemic HIF-2α inhibitors such as belzutifan have shown promise in stabilizing retinal lesions in VHL patients. Accurate differentiation from mimickers such as vasoproliferative tumours, Coats disease, and cavernous haemangiomas remains essential. KEY MESSAGES: RCH is often the first sign of VHL disease, highlighting the need for systemic evaluation. Its pathogenesis stems from HIF pathway dysregulation, with tumour size and location - especially juxtapapillary lesions - determining visual risk. Multimodal imaging is vital for diagnosis, differentiation, and monitoring. Management is individualized, using focal therapies, anti-VEGF injections, or surgery for complications, while systemic HIF-2α inhibitors like belzutifan show promise in VHL-associated cases. Early detection and a multidisciplinary approach are essential for preserving vision and managing systemic disease.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。